Opiant Pharmaceuticals Inc (OPNT.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|73||2012||Executive Chairman of the Board|
|38||2009||President, Chief Executive Officer, Director|
|58||2017||Chief Financial Officer|
|2015||Executive Vice President - Medical Affairs|
|69||2017||Chief Scientific Officer|
- BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly net Loss Per Common Share $2.77
- BRIEF-Opiant pharmaceuticals says may offer & sell its shares through Cantor Fitzgerald
- BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
- BRIEF-Opiant Pharmaceuticals reports Q4 loss per share $0.17
- BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment